the aid library

LIST OPTIONS

Filter

8612

Banking on health: the surging pandemic of health financialization

Dentico N. Society for International Development (SID) (2023) CC

In the last three decades, health financialization has surged in several creative ways, yet this growing phenomenon remains surprisingly unknown, and neglected, in the global health arena. Financialization in the health domain could be described as the uncontrolled expansion of finance along vari... more

Download (331)

View PDF (320)

Invisible women: A gender analysis of climate-induced migration in South Asia

Action Aid; CANSA; ICMPD; et al. (2021) CC

New research exposes how women and children are disproportionally affected by climate migration, which puts them at greater risk of gender-based violence, child labour and exploitation. Governments must ensure the safety and protection of women and girls in climate emergencies, including the safe... more

Download (292)

View PDF (194)

2020 Heart Failure Society of South Africa perspective on the 2016 European Society of Cardiology Chronic Heart Failure Guidelines

Hitzeroth, J.; Mpe, M.; Klug, E. et al. The South African Medical Journal (2020) CC

Heart failure with a reduced ejection fraction (HFrEF) is a condition frequently encountered by healthcare professionals and, in order to achieve the best outcomes for patients, needs to be managed optimally. This guideline document is based on the European Society of Cardiology Guidelines for the t... more

Download (334)

View PDF (387)

Democratic Republic of the Congo Country Strategic Plan (2021–2024)

World Food Program WFP (2021) CC

Food and nutrition security in the Democratic Republic of the Congo is subject to the relentless impact of conflict, epidemics and climate events that have persisted in the country for decades, further compounded by the global COVID-19 pandemic. Lack of infrastructure and investment in agriculture, ... more

Download (332)

View PDF (440)

Estimated Burden of Serious Fungal Infections in Mozambique

Jahit S, David WD (2018) C1

With this study, we estimated the burden of serious fungal infections for the general healthy population and for those at risk, including those infected with HIV, patients with asthma, as well as those under intensive care. We also highlight from studies in progress of high incidences of histoplasm... more

External Link

Humanitarian Health Ethics Analysis Tool: HEAT Handbook

Fraser V, Hunt MR, Schwartz L, and de Laat S (2014)

You can download the handbook, worksheets and quick reference cards from the website! The HHEAT is an ethical analysis tool designed to help humanitarian healthcare workers make ethical decisions. It consists of 3 components: (1) a summary card highlighting key questions, (2) a handbook providing a... more

Download (579)

View PDF (361)

Appropriate Use of Medical Resources: Antimicrobial Stewardship Toolkit

American Hospital Association AHA (2019) C2

User GuideThe toolkit is composed of three sections: Hospital and Health System Resources - includes a readiness assessment tool, the starting point in developing or enhancing a successful Antimicrobial Stewardship Program (ASP). The tool, a checklist developed by the CDC, should be shared with se... more

Download (257)

View PDF (499)

Targeting and prioritization of impoverished and food-insecure populations affected by COVID-19 | Safeguarding and scaling up assistance for people most at risk

WFP (2020) CC

The outbreak of COVID-19 comes with unpredictable primary and secondary impacts on vulnerable and food-insecure populations across the world. Mortality and morbidity appear to be most acute for elderly people, and those with underlying health conditions. At the same time, the widely anti... more

Download (247)

View PDF (251)

Waste Management during the COVID-19 Pandemic: from response to recovery

UNEP (2020) CC

A new publication - Waste Management during the COVID-19 Pandemic: from response to recovery - reviews current practices for managing waste from healthcare facilities, households and quarantine locations accommodating people with confirmed or suspected cases of COVID-19. Jointly produced by UNEP, th... more

Download (253)

View PDF (260)

WHO implementation tool for pre-exposure prophylaxis of HIV infection - Module 3

World Health Organization (WHO) World Health Organization (WHO) (2017) C_WHO

Module 3 Counsellors July 2017 Module 3: Counsellors. This module is for staff who counsel people as they consider PrEP or start taking PrEP and support them in coping with side-effects and adherence strategies. Those who counsel PrEP users may be lay, peer or professional counsellors and hea... more

Download (203)

View PDF (203)

Start with Her: UNFPA Strategy for Reproductive, Maternal and Newborn Health and Well-Being 2025–2030

United Nations Population Fund UNFPA (2025) CC

Nearly 800 women die every day from preventable maternal causes, and in 2022 alone, an estimated 2.3 million newborns died. For every maternal death, countless more women endure life-altering injuries, infections, and disabilities related to childbirth. Maternal deaths are concentrated in the poo... more

Download (179)

View PDF (166)

Asbestos-related diseases in mineworkers: a clinicopathological study

Ndlovu, N.; Rees, D.; Murray, J.; et al. ERJ Open Research, part of the European Respiratory Society (ERS) (2017) CC

This study compared clinical and autopsy findings for three asbestos-related diseases (asbestosis, mesothelioma and lung cancer) in former asbestos mineworkers, and explored factors that influenced agreement between clinical and autopsy findings using data from two compensation systems. In South Afr... more

Download (330)

View PDF (325)

Government policy interventions to reduce human antimicrobial use: A systematic review and evidence map

Van Katwyk, S. R.; Grimshaw, J. M.; et al (2019) C2

BACKGROUND: Growing political attention to antimicrobial resistance (AMR) offers a rare opportunity for achieving meaningful action. Many governments have developed national AMR action plans, but most have not yet implemented policy interventions to reduce antimicrobial overuse. A systematic evidenc...e map can support governments in making evidence-informed decisions about implementing programs to reduce AMR, by identifying, describing, and assessing the full range of evaluated government policy options to reduce antimicrobial use in humans. METHODS AND FINDINGS: Seven databases were searched from inception to January 28, 2019, (MEDLINE, CINAHL, EMBASE, PAIS Index, Cochrane Central Register of Controlled Trials, Web of Science, and PubMed). We identified studies that (1) clearly described a government policy intervention aimed at reducing human antimicrobial use, and (2) applied a quantitative design to measure the impact. We found 69 unique evaluations of government policy interventions carried out across 4 of the 6 WHO regions. These evaluations included randomized controlled trials (n = 4), non-randomized controlled trials (n = 3), controlled before-and-after designs (n = 7), interrupted time series designs (n = 25), uncontrolled before-and-after designs (n = 18), descriptive designs (n = 10), and cohort designs (n = 2). From these we identified 17 unique policy options for governments to reduce the human use of antimicrobials. Many studies evaluated public awareness campaigns (n = 17) and antimicrobial guidelines (n = 13); however, others offered different policy options such as professional regulation, restricted reimbursement, pay for performance, and prescription requirements. Identifying these policies can inform the development of future policies and evaluations in different contexts and health systems. Limitations of our study include the possible omission of unpublished initiatives, and that policies not evaluated with respect to antimicrobial use have not been captured in this review. CONCLUSIONS: To our knowledge this is the first study to provide policy makers with synthesized evidence on specific government policy interventions addressing AMR. In the future, governments should ensure that AMR policy interventions are evaluated using rigorous study designs and that study results are published. more

External Link

Trachoma Action Planning TAP

International Coalition for Trachoma Control ICTC (2022) CC

In 2011, ICTC developed a Trachoma Action Plan (TAP) planning guide to support national health officials in endemic countries. This resource was developed to complement the 2020 INSight roadmap by helping countries create specific national plans detailing how they will reach elimination targets in t... more

Download (349)

View PDF (425)

Online Training of Trainers in Psychological First Aid

The International Federation of Red Cross and Red Crescent Societies IFRC (2022) C1

The COVID-19 pandemic has impacted the world and consequently increased MHPSS needs across various contexts. While National Societies respond to the rising mental health and psychosocial support needs, they are also adapting to and implementing remote support, such as telephone hotlines or other onl... more

External Link

Donor Funding for Newborn Survival: An Analysis of Donor-Reported Data, 2002–2010

Pitt1, C.; J. E. Lawn; M. Ranganathan et al. PLoS Med (2012) CC

Background:Neonatal mortality accounts for 43% of global under-five deaths and is decreasing more slowly than maternal or child mortality. Donor funding has increased for maternal, newborn, and child health (MNCH), but no analysis to date has disaggregated aid for newborns. We evaluated if and how a... more

External Link

World Heart Federation Roadmap on Atrial Fibrillation – A 2020 Update

Freedman, B.; Hindricks, G.; Banerjee, A. Global Heart (2021) CC

The World Heart Federation (WHF) commenced a Roadmap initiative in 2015 to reduce the global burden of cardiovascular disease and resultant burgeoning of healthcare costs. Roadmaps provide a blueprint for implementation of priority solutions for the principal cardiovascular diseases leading to death... more

Download (468)

View PDF (696)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (270)

View PDF (259)

Malaria Operational Plan FY 2018 Ethiopia

United States Agency for International Development United States Agency for International Development (2018) C1

This FY 2018 Malaria Operational Plan (MOP) presents a detailed implementation plan for Ethiopia, based on the strategies of PMI and the National Malaria Control Program (NMCP). It was developed in consultation with the Federal Ministry of Health (FMOH), NMCP, Ethiopian Public Health Institute (EP... more

Download (196)

View PDF (375)

Proposed Strategies to Improve Adult Asthma Management in Egypt: Expert Review and Recommendations

Hosny, H.; Madkour, A.; Hantera, M.; et al. (2022) CC2

Several challenges face asthma management in Egypt, including the high percentage of uncontrolled patients, inadequate compliance, and overuse of short-acting beta-agonists (SABAs) leading to increased asthma-related morbidity and mortality. In this regard, the recent Global Initiative for Asthma (G... more